Stereotactic interstitial irradiation of diencephalic tumors with iridium 192 and iodine 125: 10 years follow-up and comparison with other treatments

1989 ◽  
Vol 5 (3) ◽  
pp. 140-143 ◽  
Author(s):  
A. Etou ◽  
F. Mundinger ◽  
M. Mohadjer ◽  
W. Birg
Keyword(s):  
Interstitial Irradiation ◽  
Iridium 192 ◽  
Iodine 125

Dosimetric Calculations and Measurements of Gold Plaque Ophthalmic Irradiators Using Iridium-192 and Iodine-125 Seeds

1989 ◽  
Vol 14 (1) ◽  
pp. 58
Author(s):  
Gary Luxton ◽  
Melvin A. Astrahan ◽  
Peter E. Liggett ◽  
David L. Neblett ◽  
Dierdre M. Cohen ◽  
...  
Keyword(s):  
Iridium 192 ◽  
Iodine 125

Iodine-125 interstitial brachytherapy after tumor excision: an alternative eye-sparing surgery for lacrimal gland carcinoma

2021 ◽  
Author(s):  
Yang-jun Li ◽  
Ping Wang ◽  
Shao-bo Zhang ◽  
Xiao-na Ning ◽  
Chen-jun Guo ◽  
...  
Keyword(s):  
Lacrimal Gland ◽  
Tumor Recurrence ◽  
Tumor Resection ◽  
Interstitial Brachytherapy ◽  
Tumor Excision ◽  
Control Tumor ◽  
Gland Carcinoma ◽  
Iodine 125 ◽  
Good Cosmesis

Abstract Background:To describe the preliminary suppressive effects of iodine 125 brachytherapy for malignant lacrimal gland tumors after excisionMethods:The study recruit 9 patients with lacrimal gland carcinoma from May 2017 to December 2020. All patients underwent eye sparing surgical tumor resection first and then received iodine 125 interstitial brachytherapy to prevent tumor recurrence. We look over whether tumor recurred or metastasized by detecting the visual function and CT/MRI/PET MRI of every patient.Results1 patient was lost visit. The median follow up period was 29 months of other 8 patients (range, 7 43 months). One patient experienced recurrence two years later but was free from local disease after iodine 125 seeds were implanted one more time. The vision of one female patient was lost due to the seeds moving to the optic nerve. In the remaining 6 patients the vision was no changed, and CT/MRI showed no tumor was recurrencedConclusions:Permanent iodine 125 strip implantation in the orbit can be used as an alternative eye sparing surgery for malignant lacrimal gland tumors after tumor excision. It can control tumor recurrence and maintenance of vision and good cosmesis.

Radiation Control in the Intensive Care Unit for High Intensity Iridium-192 Brain Implants

Neurosurgery ◽  
1987 ◽  
Vol 20 (4) ◽  
pp. 584-588 ◽  
Author(s):  
Wilfred Sewchand ◽  
Robert E. Drzymala ◽  
Pradip P. Amin ◽  
Michael Salcman ◽  
Omar M. Salazar
Keyword(s):  
Intensive Care Unit ◽  
Intensive Care ◽  
High Intensity ◽  
Exposure Level ◽  
Brain Irradiation ◽  
Radiation Control ◽  
Radium Equivalent ◽  
Iridium 192 ◽  
Iodine 125 ◽  
Nursing Teams

Abstract A bedside lead cubicle was designed to minimize the radiation exposure of intensive care unit staff during routine interstitial brain irradiation by removable, high intensity iridium-192. The cubicle shields the patient without restricting intensive care routines. The design specifications were confirmed by exposure measurements around the shield with an implanted anthropomorphic phantom simulating the patient situation. The cubicle reduces the exposure rate around an implant patient by as much as 90%, with the exposure level not exceeding 0.1 mR/hour/mg of radium-equivalent 192Ir. Evaluation of data accumulated for the past 3 years has shown that the exposure levels of individual attending nurses are 0.12 to 0.36 mR/mg of radium-equivalent 192Ir per 12-hour shift. The corresponding range for entire nursing teams varies between 0.18 and 0.26. A radiation control index (exposure per mg of radium-equivalent 192Ir per nurse-hour) is thus defined for individual nurses and nursing teams; this index is a significant guide to the planning of nurse rotations for brain implant patients with various 192Ir loads. The bedside shield reduces exposure from 192Ir implants by a factor of about 20, as expected, and the exposure from the lower energy radioisotope iodine-125 is barely detectable.

Brachytherapy of recurrent malignant brain tumors with removable high-activity iodine-125 sources

1984 ◽  
Vol 60 (1) ◽  
pp. 61-68 ◽  
Author(s):  
Philip H. Gutin ◽  
Theodore L. Phillips ◽  
William M. Wara ◽  
Steven A. Leibel ◽  
Yoshio Hosobuchi ◽  
...  
Keyword(s):  
Brain Tumors ◽  
High Activity ◽  
Anaplastic Astrocytoma ◽  
Tumor Regression ◽  
Chemotherapeutic Agents ◽  
Content Type ◽  
Iodine 125 ◽  
Initial Implantation ◽  
Fine Print

✓ Thirty-seven patients harboring recurrent malignant primary or metastatic brain tumors were treated by 40 implantations of high-activity iodine-125 (125I) sources. All patients had been treated with irradiation and most had been treated with chemotherapeutic agents, primarily nitrosoureas. Implantations were performed using computerized tomography (CT)-directed stereotaxy; 125I sources were held in one or more afterloaded catheters that were removed after the desired dose (minimum tumor dose of 3000 to 12,000 rads) had been delivered. Patients were followed with sequential neurological examinations and CT scans. Results of 34 implantation procedures were evaluable: 18 produced documented tumor regression (response) for 4 to 13+ months; five, performed in deteriorating patients, resulted in disease stability for 4 to 12 months. The overall response rate was 68%. In 11 patients, implantation did not halt clinical deterioration. At exploratory craniotomy 5 to 12 months after implantation, focal radiation necrosis was documented in two patients whose tumor had responded initially and then progressed, and in three patients whose disease had progressed initially (four glioblastomas, one anaplastic astrocytoma); histologically identifiable tumor was documented in two of these patients. All improved after resection of the focal necrotic mass and are still alive 10, 15, 19, 24, and 25 months after the initial implantation procedure; only one patient has evidence of tumor regrowth. The median follow-up period after implantation for the malignant glioma (anaplastic astrocytoma and glioblastoma multiforme) group is 9 months, with 48% of patients still surviving. While direct comparison with the results of chemotherapy is difficult, results obtained in this patient group with interstitial brachytherapy are probably superior to results obtained with chemotherapy.

Sign in / Sign up

Export Citation Format

Share Document